90 related articles for article (PubMed ID: 19620819)
41. Novel antineoplastics targeting genetic changes in colorectal cancer.
Joudeh J; Allen JE; Das A; Prabhu V; Farbaniec M; Adler J; El-Deiry WS
Adv Exp Med Biol; 2013; 779():1-34. PubMed ID: 23288633
[TBL] [Abstract][Full Text] [Related]
42. BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer.
Lea A; Allingham-Hawkins D; Levine S
PLoS Curr; 2010 Oct; 2():RRN1187. PubMed ID: 20972475
[TBL] [Abstract][Full Text] [Related]
43. Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review.
Cepero A; Luque C; Cabeza L; Perazzoli G; Quiñonero F; Mesas C; Melguizo C; Prados J
Int J Nanomedicine; 2022; 17():5065-5080. PubMed ID: 36345508
[TBL] [Abstract][Full Text] [Related]
44. Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis.
Neyns B; Meert V; Vandenbroucke F
Curr Oncol; 2008 Aug; 15(4):196-7. PubMed ID: 18769609
[TBL] [Abstract][Full Text] [Related]
45. The potential of monoclonal antibodies for colorectal cancer therapy.
Heidari F; Madadi S; Alizadeh N; Alimardani MH; Safari A; Armand MH; Pishgahzadeh E; Soleimani M
Med Oncol; 2023 Aug; 40(9):273. PubMed ID: 37603117
[TBL] [Abstract][Full Text] [Related]
46. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review.
Fornasier G; Francescon S; Baldo P
Adv Ther; 2018 Oct; 35(10):1497-1509. PubMed ID: 30218345
[TBL] [Abstract][Full Text] [Related]
47. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
48. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
49. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
50. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
51. [Cetuximab (Erbitux)].
Shimoyama T
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1203-12. PubMed ID: 19620819
[TBL] [Abstract][Full Text] [Related]
52. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
